A Critical Assessment of Items on the Pediatric Crohn's Disease Activity Index

ObjectivesQuestions have been raised about the discriminative value of the three laboratory items (hematocrit, erythrocyte sedimentation rate, and albumin) and three physical items (height, perirectal disease, and extraintestinal manifestations) included in the Pediatric Crohn's Disease Activity Index (PCDAI). The aim of this study was to analyze the value of these six “criticized” items to the discriminative properties of the PCDAI. MethodsData from 71 children with Crohn's disease visiting an outpatient clinic were analyzed. Physician global assessment of disease activity was used as the gold standard. A “basic index” was calculated by subtracting the score of the six criticized items from the score of the PCDAI calculated in the standard fashion. Multivariate logistic regression procedures identified which items significantly contributed to the “basic index”. Receiver operating characteristic curves were produced comparing the standard PCDAI score to the “basic index” and a new “clinical index” which included only the criticized items truly contributing to the discriminatory ability of the “basic index”. ResultsLogistic regression models identified only perirectal disease as contributing to the discriminative abilities of the basic index. The clinical index therefore consists of the three history items (abdominal pain, number of liquid stools, and general well-being), three physical examination items (weight loss, abdominal examination, and perirectal disease) and no laboratory tests. The clinical index had an area under the curve not significantly inferior to that of the original PCDAI (0.93 [95% confidence interval, 0.89–0.99] vs. 0.96 [95% confidence interval, 0.92–0.99]). ConclusionsA clinical index consisting of three history items and three physical examination items has an accuracy equal to the standard PCDAI in distinguishing children with disease in remission from those with a relapse.

[1]  A. Griffiths,et al.  Controlled Ileal Release Budesonide in Pediatric Crohn Disease: Efficacy and Effect on Growth , 2001, Journal of pediatric gastroenterology and nutrition.

[2]  A. Griffiths,et al.  Oral tacrolimus treatment of severe colitis in children. , 2000, The Journal of pediatrics.

[3]  S. Kugathasan,et al.  Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease , 2000, American Journal of Gastroenterology.

[4]  J. Markowitz,et al.  A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. , 2000, Gastroenterology.

[5]  J. Hyams Use of Infliximab in the Treatment of Crohn's Disease in Children and Adolescents , 2000, The Journal of pediatrics.

[6]  I. Bjarnason,et al.  Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. , 2000, Gastroenterology.

[7]  B. Vainer,et al.  Established and emerging biological activity markers of inflammatory bowel disease. , 2000, The American journal of gastroenterology.

[8]  M. Corey,et al.  Assessing activity of pediatric Crohn's disease: which index to use? , 1999, Gastroenterology.

[9]  S. Targan,et al.  Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. , 1998, Gastroenterology.

[10]  E. Hassall,et al.  Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children. , 1996, The American journal of gastroenterology.

[11]  M. Mäki,et al.  Exclusive Whole Protein Enteral Diet Versus Prednisolone in the Treatment of Acute Crohn's Disease in Children , 1994, Journal of pediatric gastroenterology and nutrition.

[12]  A. Griffiths,et al.  Relationship of Common Laboratory Parameters to the Activity of Crohn's Disease in Children , 1992, Journal of pediatric gastroenterology and nutrition.

[13]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[14]  H. Hildebrand,et al.  Chronic Inflammatory Bowel Disease in Children and Adolescents in Sweden , 1991, Journal of pediatric gastroenterology and nutrition.

[15]  J T Boyle,et al.  Development and validation of a pediatric Crohn's disease activity index. , 1991, Journal of pediatric gastroenterology and nutrition.

[16]  F. Bartholomeusz,et al.  Measurement of activity in Crohn's disease , 1989, Journal of gastroenterology and hepatology.

[17]  B. Davies,et al.  HEPATOTOXICITY OF TETRAHYDROACRIDINE , 1988, The Lancet.

[18]  B. Richards,et al.  Laboratory Assessment of Disease Activity in Childhood Crohn's Disease and Ulcerative Colitis , 1986, Journal of pediatric gastroenterology and nutrition.

[19]  F. T. de Dombal,et al.  The O.M.G.E. Multinational Inflammatory Bowel Disease Survey 1976-1982. A further report on 2,657 cases. , 1984, Scandinavian journal of gastroenterology. Supplement.

[20]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[21]  A. Harries,et al.  Platelet count: a simple measure of activity in Crohn's disease. , 1983, British medical journal.

[22]  R. Newcombe,et al.  CONTROLLED TRIAL OF SUPPLEMENTED ORAL NUTRITION IN CROHN'S DISEASE , 1983, The Lancet.

[23]  J. Fermanian,et al.  Assessment of appropriate laboratory measurements to supplement the Crohn's disease activity index. , 1981, Gut.

[24]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.

[25]  A. Griffiths,et al.  Antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibody: clinical tools or clues for research? , 2000, Journal of Pediatric Gastroenterology and Nutrition - JPGN.